Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant 9vHPV and mRNA-1273 vaccination in children aged 9 to 11 years
2021-003591-13Phase 3
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine and elasomeran in human papillomavirus infection and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Merck & Co. Primary endpoint: Geometric Mean Titers of Anti-Human Papillomavirus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
02
Drugs
recombinant human papillomavirus 9-valent vaccineelasomeran
03
Conditions
human papillomavirus infectioncoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003591-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003591-13.